MX2018013973A - Metodos de tratamiento de sindromes de comportamiento usando pipradrol. - Google Patents
Metodos de tratamiento de sindromes de comportamiento usando pipradrol.Info
- Publication number
- MX2018013973A MX2018013973A MX2018013973A MX2018013973A MX2018013973A MX 2018013973 A MX2018013973 A MX 2018013973A MX 2018013973 A MX2018013973 A MX 2018013973A MX 2018013973 A MX2018013973 A MX 2018013973A MX 2018013973 A MX2018013973 A MX 2018013973A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- pipradrol
- treating behavioral
- behavioral syndromes
- syndromes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se proporcionan métodos para tratar síndromes de comportamiento mediante la administración de una composición farmacéutica de pipradrol o una sal farmacéuticamente aceptable del mismo. Los métodos pueden usarse para tratar el Trastorno de Déficit de Atención (TDA) y el Trastorno de Déficit de Atención e hiperactividad (TDAH).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662341855P | 2016-05-26 | 2016-05-26 | |
PCT/US2017/034443 WO2017205606A1 (en) | 2016-05-26 | 2017-05-25 | Methods of treating behavioral syndromes using pipradrol |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018013973A true MX2018013973A (es) | 2019-03-28 |
Family
ID=60408578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018013973A MX2018013973A (es) | 2016-05-26 | 2017-05-25 | Metodos de tratamiento de sindromes de comportamiento usando pipradrol. |
Country Status (10)
Country | Link |
---|---|
US (3) | US9827233B1 (es) |
EP (1) | EP3439657A4 (es) |
JP (1) | JP2019517469A (es) |
KR (1) | KR20190013737A (es) |
CN (1) | CN109414435A (es) |
AU (1) | AU2017268795A1 (es) |
CA (1) | CA3025473A1 (es) |
IL (1) | IL262986A (es) |
MX (1) | MX2018013973A (es) |
WO (1) | WO2017205606A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9351968B1 (en) * | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
EP3439657A4 (en) * | 2016-05-26 | 2019-12-18 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISTURBANCES USING PIPRADROL |
KR20200053570A (ko) * | 2017-09-12 | 2020-05-18 | 오비드 테라퓨틱스 인크. | 기면증의 치료에서 가복사돌의 사용 |
WO2020061410A1 (en) | 2018-09-20 | 2020-03-26 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
JP2022514194A (ja) | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
CN113423399A (zh) | 2018-12-17 | 2021-09-21 | 奥维德医疗公司 | 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途 |
GB201911056D0 (en) * | 2019-08-02 | 2019-09-18 | Sanchez Hector Mario | Treatment of ADD/ADHD |
IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | A canceled gaboxadol ring and its use for the treatment of psychiatric disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2830083A (en) | 1953-04-29 | 1958-04-08 | Allied Chem & Dye Corp | Production of aryloxy aliphatic carboxylic acids |
US3947579A (en) | 1974-06-03 | 1976-03-30 | Nelson Research & Development Company | Method and composition for potentiating neuroleptic drugs |
US4084000A (en) | 1975-07-16 | 1978-04-11 | Nelson Research And Development Company | Method of treating schizophrenia |
US4129652A (en) | 1976-08-16 | 1978-12-12 | Nelson Research & Development Company | Method for potentiating neuroleptic drugs |
US5650521A (en) * | 1995-12-29 | 1997-07-22 | Guilford Pharmaceuticals Inc. | Pyrrolidine derivatives |
AU2007346591A1 (en) * | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of ADHD |
WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
US8865746B2 (en) | 2008-07-18 | 2014-10-21 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
FR2935611B1 (fr) | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
US20100260844A1 (en) * | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
WO2011020030A2 (en) * | 2009-08-13 | 2011-02-17 | The General Hospital Corporation | Methods and compositions to prevent addiction |
ES2595251T3 (es) | 2010-05-25 | 2016-12-28 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Métodos y composición farmacéutica para el tratamiento de un trastorno alimentario con inicio temprano en un paciente |
PT3272342T (pt) * | 2011-03-23 | 2021-07-12 | Ironshore Pharmaceuticals & Dev Inc | Processos e composições para o tratamento de síndrome de défice de atenção |
US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
EP3439657A4 (en) * | 2016-05-26 | 2019-12-18 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISTURBANCES USING PIPRADROL |
-
2017
- 2017-05-25 EP EP17803569.7A patent/EP3439657A4/en not_active Withdrawn
- 2017-05-25 AU AU2017268795A patent/AU2017268795A1/en not_active Abandoned
- 2017-05-25 CA CA3025473A patent/CA3025473A1/en not_active Abandoned
- 2017-05-25 CN CN201780032282.5A patent/CN109414435A/zh active Pending
- 2017-05-25 US US15/604,776 patent/US9827233B1/en active Active
- 2017-05-25 KR KR1020187032669A patent/KR20190013737A/ko not_active Application Discontinuation
- 2017-05-25 WO PCT/US2017/034443 patent/WO2017205606A1/en active Application Filing
- 2017-05-25 MX MX2018013973A patent/MX2018013973A/es unknown
- 2017-05-25 JP JP2018561714A patent/JP2019517469A/ja active Pending
- 2017-10-19 US US15/788,168 patent/US20180036298A1/en not_active Abandoned
-
2018
- 2018-11-08 US US16/183,933 patent/US10493069B2/en active Active
- 2018-11-13 IL IL262986A patent/IL262986A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3025473A1 (en) | 2017-11-30 |
US20170340619A1 (en) | 2017-11-30 |
WO2017205606A1 (en) | 2017-11-30 |
CN109414435A (zh) | 2019-03-01 |
US9827233B1 (en) | 2017-11-28 |
US10493069B2 (en) | 2019-12-03 |
US20190076415A1 (en) | 2019-03-14 |
AU2017268795A1 (en) | 2018-11-22 |
JP2019517469A (ja) | 2019-06-24 |
KR20190013737A (ko) | 2019-02-11 |
US20180036298A1 (en) | 2018-02-08 |
EP3439657A1 (en) | 2019-02-13 |
EP3439657A4 (en) | 2019-12-18 |
IL262986A (en) | 2018-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018013973A (es) | Metodos de tratamiento de sindromes de comportamiento usando pipradrol. | |
PH12016501790A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
NZ761388A (en) | Methods of treatment for cystic fibrosis | |
SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
PH12016501788A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
MX2017004471A (es) | Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística. | |
MY188139A (en) | Sodium channel modulators for the treatment of pain | |
MX2021007651A (es) | Inhibidores de ezh2 para tratar linfomas. | |
EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
MX2015009276A (es) | Donadores de nitroxilo con indice terapeutico mejorado. | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
MX2020001428A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
NZ725354A (en) | Transdermal formulations of pergolide and uses thereof | |
MX2019008000A (es) | Metodo de administracion de compuestos donadores de nitroxilo. | |
MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
AR107027A1 (es) | Moduladores de actividad complementaria |